Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Aprea Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DOYLESTOWN, PA., DEC. 18, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT TARGET WEAKNESSES IN CANCER CELLS WHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY ISSUED THE FOLLOWING LETTER TO SHAREHOLDERS FROM CHIEF EXECUTIVE OFFICER, OREN GILAD. THE LETTER HIGHLIGHTS THE COMPANY'S ONGOING CLINICAL PROGRESS, OPERATIONAL EXECUTION, AND PLANS FOR 2026.

APREA THERAPEUTICS CEO ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTING PIPELINE PROGRESS IN 2025 AND OUTLOOK FOR 2026

FINANCING FROM NEW AND EXISTING HEALTHCARE FOCUSED INVESTORS THE PROCEEDS ARE EXPECTED TO EXTEND THE COMPANY'S CASH RUNWAY INTO Q1 2027, WITH POTENTIAL INFLECTION POINTS ANTICIPATED IN ITS CLINICAL PROGRAMS DURING THAT PERIOD DOYLESTOWN, PA., DEC. 09, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIES WHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH NEW AND EXISTING HEALTHCARE FOCUSED INVESTORS AND CERTAIN INSIDERS OF THE COMPANY TO SELL AN AGGREGATE OF 2,623,023 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN-LIEU THEREOF), TOGETHER WITH WARRANTS TO PURCHASE UP TO AN AGGREGATE 2,623,023 SHARES OF COMMON STOCK, IN A PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES (THE OFFERING).

APREA THERAPEUTICS ANNOUNCES $3.1 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

APR-1051 (WEE1 KINASE INHIBITOR): IN ONGOING PHASE 1 ACESOT-1051DOSE-ESCALATION TRIAL, 3 OUT OF 4 PATIENTS AT DOSE LEVEL 6 (100 MG ONCE DAILY) ACHIEVED STABLE DISEASE, PER RECIST V1.1, IN HEAVILY PRETREATED GASTROINTESTINAL AND GYNECOLOGIC MALIGNANCIES ATRN-119 (ATR KINASE INHIBITOR): RP2D OF 1,100 MG ONCE DAILY IDENTIFIED IN ABOYA-119 DOSE-ESCALATION STUDY POSTERS ON APR-1051 AND ATRN-119 FEATURED AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS DOYLESTOWN, PA., NOV. 12, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIESWHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE.

APREA THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CLINICAL UPDATE

DOYLESTOWN, PA., OCT. 24, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIES WHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY PROVIDED AN UPDATE ON THE ONGOING PHASE 1 ACESOT-1051 (A MULTI-CENTER EVALUATION OF WEE1 INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS, APR-1051) STUDY. THE LATEST RESULTS SHOW THAT, AT THE 100 MG APR-1051 DOSE LEVEL, 3 OUT OF 4 PATIENTS ACHIEVED STABLE DISEASE, AS MEASURED USING RECIST V1.1 CRITERIA.

Aprea Therapeutics, Inc.

APRE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Aprea Therapeutics, Inc.

APRE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

APRE